Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA.

Clin Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16.

2.

Bosutinib: a novel second-generation tyrosine kinase inhibitor.

Isfort S, Keller-v Amsberg G, Schafhausen P, Koschmieder S, Brümmendorf TH.

Recent Results Cancer Res. 2014;201:81-97. doi: 10.1007/978-3-642-54490-3_4. Review.

PMID:
24756786
3.

Bosutinib for the treatment of chronic myeloid leukemia.

Doan V, Wang A, Prescott H.

Am J Health Syst Pharm. 2015 Mar 15;72(6):439-47. doi: 10.2146/ajhp140221. Review.

PMID:
25736937
4.

Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.

Stansfield L, Hughes TE, Walsh-Chocolaad TL.

Ann Pharmacother. 2013 Dec;47(12):1703-11. doi: 10.1177/1060028013503124. Review.

PMID:
24396109
5.

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.

Keller G, Schafhausen P, Brummendorf TH.

Expert Rev Hematol. 2009 Oct;2(5):489-97. doi: 10.1586/ehm.09.42. Review.

PMID:
21083014
6.

Bosutinib.

Keller G, Schafhausen P, Brümmendorf TH.

Recent Results Cancer Res. 2010;184:119-27. doi: 10.1007/978-3-642-01222-8_9. Review.

PMID:
20072835
7.

Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.

Keller-V Amsberg G, Brümmendorf TH.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1121-7. doi: 10.1586/era.12.84. Review.

PMID:
23098112
8.

Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Irvine E, Williams C.

Pharmacotherapy. 2013 Aug;33(8):868-81. doi: 10.1002/phar.1266. Epub 2013 Apr 3. Review.

PMID:
23553655
9.

Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.

Boschelli F, Arndt K, Gambacorti-Passerini C.

Eur J Cancer. 2010 Jul;46(10):1781-9. doi: 10.1016/j.ejca.2010.02.032. Review.

PMID:
20399641
10.

Novel dual Src/Abl inhibitors for hematologic and solid malignancies.

Schenone S, Brullo C, Musumeci F, Botta M.

Expert Opin Investig Drugs. 2010 Aug;19(8):931-45. doi: 10.1517/13543784.2010.499898. Review.

PMID:
20557276
11.

Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.

Abbas R, Hsyu PH.

Clin Pharmacokinet. 2016 Apr 25. [Epub ahead of print] Review.

PMID:
27113346
Items per page

Supplemental Content

Write to the Help Desk